1 / 20

Sector Analysis Healthcare

Sector Analysis Healthcare. Anurup Upadhyay BUS 416 Investment Management 3/5/14. What Does Healthcare Constitute?. The Healthcare Industry. A category of stocks relating to medical and healthcare goods or services

lynde
Télécharger la présentation

Sector Analysis Healthcare

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sector AnalysisHealthcare Anurup Upadhyay BUS 416 Investment Management 3/5/14

  2. What Does Healthcare Constitute?

  3. The Healthcare Industry • A category of stocks relating to medical and healthcare goods or services • Hospital management firms, HMOs, biotechnology and medical products’ providers • Typically considered defensive stocks • Typically less sensitive to business cycle fluctuations - Investopedia.com

  4. More Specifically… - Yahoo Finance

  5. S&P 500 Sector Breakdown - S & P Dow Jones Indices

  6. SMIF Holdings in HealthcareAs of 2/16/14

  7. Leading Sub-Sectors - Yahoo Finance, as of Feb. 25, 2014

  8. 2014 Global Healthcare Sector Outlook • Global health care spending as a percentage of Gross Domestic Product (GDP) to average 10.5% • Annual average spending to increase by 5.3% • Emerging markets: China, India, Indonesia, Russia, Mexico - Deloitte Touche Tohmatsu Limited

  9. Top Issues and Trends • Aging Population and Chronic Diseases • Cost and Quality • Access to Care • Technology - Deloitte Touche Tohmatsu Limited

  10. The Good News for 2014 • Biotech and medical devices and equipment rank in top five for corporate venture capital investments • Biotech second @ $644.95 million • Medical devices & equipment fourth @ 340.73 million • Research and development an economic engine in consumers’ eyes • 69% agreed in 2013 while 61% agreed in 2011 - PricewaterhouseCoopers LLP

  11. A Case For Biotechnology • Highest P/E in the industry; although volatile/unpredictable • New discoveries for disease treatment conducive to growth/gains in stockholder value • Patented biotech drugs enjoy a 12-year period of protection from competitors, guaranteeing favorable long-term returns • Hurdles: Short-term losses FDA regulation

  12. I am recommending that we buy 57 shares of Amgen, Inc. for approximately $126.18 per share for an approximate total of $7192.26. This represents approximately 2.87% of the portfolio. Why 2.87%? = S&P 500 Healthcare Weight – SMIF Healthcare Weight = 13.7% - 10.83% = 2.87%

  13. Established in 1980; discovers, develops, manufactures and markets human therapeutics based on cellular and molecular biologyadvances • Presence in more than 50 countries worldwide • Specializes in treatment of cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses • First-of-its-kind company to heavily research human therapeutics (eg. Immunotherapy) - Amgen Official Website

  14. Amgen, Inc. Developments 2013-14 • Amgen-BettaPharmaceuticals joint venture established in China • Amgen Astellas BioPharma K.K. announces Japan alliance • Amgen breaks ground on innovative manufacturing facility in Singapore • Amgen acquires Onyx Pharmaceuticals - Yahoo Finance, NY Times, Amgen Official Website

  15. Amgen vs. S&P 500 - MSN Money, 2014

  16. Overview & Comparison

  17. Value Line Highlights (Dec, 2013) • Timeliness: 3; Safety: 1; Technical: 3 • Strong product portfolio to facilitate continued growth, stability • Broadening customer base(Onyx) • Numerous clinical trials ongoing • A nice addition to just about any account

  18. What Do Analysts Say? • Thomson Reuters (Feb., 2014):

  19. What Do Analysts Say? • Zack’s Rating (Feb. 28, 2014): • Neutral – Outperform ($148) • One of the five strong buy stocks • Seeking Alpha (Feb., 2014) • Amgen to see significant sales growth between now and 2017 and continued sales growth through 2023 due to growth from Onyx-acquired products • Growth from Amgen's current pipeline products without even considering future pipeline products • Important to select undervalued stocks and Amgen one of them

  20. Questions

More Related